PYPD
PolyPid Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$4.88
+3.39%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$5.00
From 52W high−12.54%
Volume110676.00
Market cap$99.12M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$5.00
From 52W high
−12.54%
Volume
110676.00
Market cap
$99.12M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
P/E (TTM)
—
RSI (14)
44.2
MomentumView details →
1D Return
+3.39%
YTD Return
+12.44%
SummaryUpdated Jun 1, 2026
PolyPid Ltd. (NASDAQ:PYPD) is an Israeli late-stage biopharmaceutical company founded in 2008 and headquartered in Petah Tikva, Israel. The company went public in June 2020 and focuses on developing innovative drug delivery solutions using its proprietary polymer-lipid encapsulation matrix (PLEX) platform technology. PolyPid is currently in Phase III clinical trials with its lead product candidate D-PLEX100, designed to prevent surgical site infections, representing a significant unmet medical need in healthcare settings.
Similar companies
Latest newsMore news →
Hunger Pangs filed a draft prospectus for an IPO comprising a fresh issue of equity shares worth Rs 150 crore and an offer for sale of up to 2.79 crore shares by existing shareholders.3d agoPolyPid Ltd. announced that it will host a virtual investor day on October 28, 2026, to outline its long-term vision and pipeline strategy, with Warren S. Joseph, DPM, FIDSA, featured.5d ago